FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

<img src='https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4382x2921+0+0/resize/4382x2921!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fe6%2F9c%2Feae035dd4eadb09df9cd11ac3650%2Fgettyimages-1288670273.jpg' alt='Moderna will soon learn the regulatory fate of its mRNA-based flu shot.'/><p>The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.</p><p>(Image credit: Maddie Meyer)</p><img src='https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=nx-s1-5897441' />